



## **Further information on changes to Board of NeuroScientific**

As per NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) ("**NeuroScientific**") previous announcement on 13 November 2023 regarding changes to the Board of NeuroScientific, the material terms of the appointments of Mr Clarke Barlow and Mr Chris Ntoumenopoulos are detailed below:

For their services as Non-executive directors both Mr Chris Ntoumenopoulos and Mr Clarke Barlow will be paid a fee of \$50,000 per annum respectively.

In addition, effective 13 November 2023, Mr Paul Rennie's fee for his services as a Non-executive Chair of the board will reduce to \$100,000 per annum and Dr Anton Uvarov's fee for his services as Non-executive director will reduce to \$50,000 per annum.

This announcement is authorised by the board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS

For more information please contact:

Paul Rennie  
Non-executive Chair  
ir@neuroscientific.com  
+ 61 8 6382 1805

Abby Macnish Niven  
CFO and Company Secretary  
ir@neuroscientific.com  
+ 61 8 6382 1805

### **About NeuroScientific Biopharmaceuticals Ltd**

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit [www.neuroscientific.com](http://www.neuroscientific.com)

### **About EmtinB™**

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.